Leverkusen, Germany-based drugmaker Bayer (BAYN: DE) has been granted approval in Europe for Jivi (recombinant factor VIII concentrate).
The approval comes three months after the US regulator gave the hemophilia A therapy the nod, and two months after it was approved in Japan.
Jivi is the third hemophilia A treatment in Bayer's portfolio, after Kogenate (recombinant antihemophilic factor) and Kovaltry (recombinant antihemophilic factor), which had combined sales of 967 million euros ($1.13 billion) in 2017.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze